Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799043 · ClinicalTrials.gov registry record · NA
Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 269
- Enrollment target
NCT02799043: Completed NA study, sponsored by Abbott Medical Devices.
NCT02799043 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 269 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02799043, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 269 participants
- Enrollment target
Study Summary
A prospective, multicenter, randomized study to assess the safety and effectiveness of FIRM-guided procedures in conventional "redo" RF ablation procedures for the treatment of persistent and paroxysmal atrial fibrillation.
Primary Outcome
Single procedure freedom from recurrence from 3-12 months post procedure
Interventions
- PROCEDURE FIRM-Guided Procedure and PVI
- PROCEDURE Standard PVI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-07 |
| Phase | NA |
What the finished NCT02799043 record still lists
NCT02799043 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which FIRM-Guided Procedure and PVI is the first listed.
NCT02799043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02799043 about?
NCT02799043 is a clinical study titled "Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures". A prospective, multicenter, randomized study to assess the safety and effectiveness of FIRM-guided procedures in conventional "redo" RF ablation procedures for the treatment of persistent and paroxysmal atrial fibrillation.
What is the current status of trial NCT02799043?
This trial is currently completed. It is a NA study. The enrollment target is 269 participants. The study started on 2016-06. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02799043?
The interventions under investigation include: FIRM-Guided Procedure and PVI (PROCEDURE), Standard PVI (PROCEDURE).
Who is sponsoring clinical trial NCT02799043?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02799043's enrollment target sits among peer trials
269 392nd of 2000 higher than 1,609 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia